News & Updates

Stay informed with the latest provider updates, pricing changes, and industry news in the GLP-1 medication space.

News

July 2026: The Medicare GLP-1 Bridge Goes Live, Foundayo Joins Medicare, and the Compounding Comment Window Closes

July 1 was the day Medicare's $50 GLP-1 Bridge finally turned on — Foundayo, all Wegovy formulations, and the Zepbound KwikPen now cost eligible beneficiaries a flat $50/month. Meanwhile the FDA's compounding comment period closed, Wegovy's $199 intro reset, and a most-favored-nation deal reset Medicare's list prices. Here's everything that changed for July.

Jul 3, 2026 By MatchGLP1 Research Team
Read News
News

How the Medicare GLP-1 Bridge Actually Works: Prior Authorization, Claims, and the $50 Copay Explained

The Medicare GLP-1 Bridge launched July 1, 2026, giving eligible Part D beneficiaries Wegovy, Zepbound KwikPen, and Foundayo for a flat $50/month. But the fine print is unusual: claims run through a CMS central processor instead of your Part D plan, prior authorization requires a sworn attestation, and the copay doesn't count toward your out-of-pocket cap. Here's a complete, sourced walkthrough of how it works.

Jul 3, 2026 By MatchGLP1 Research Team
Read
News

May 2026: Wegovy HD Goes Nationwide, Foundayo Hits Telehealth, and FDA Moves to Permanently Ban Compounded GLP-1s

April delivered the biggest GLP-1 catalyst in years — Wegovy HD launched nationwide, Lilly's Foundayo pill hit pharmacies and telehealth, Medicare Zepbound coverage went live, and the FDA proposed a permanent ban on mass compounding of semaglutide and tirzepatide. Here's what changed and what it means for your provider choice.

May 3, 2026 By MatchGLP1 Research Team
Read
News

FDA Approves Foundayo: Eli Lilly's GLP-1 Pill You Can Take Anytime, No Restrictions

Foundayo (orforglipron) is now FDA-approved for weight loss — the only GLP-1 pill with no food or water restrictions. Here's what it costs, how it compares to Wegovy and Zepbound, and when insurance will cover it.

Apr 9, 2026 By MatchGLP1 Research Team
Read
News

April 2026: Wegovy HD Approved, Hims Pivots to Branded, and Medicare GLP-1 Coverage Begins

The GLP-1 market hits an inflection point — FDA approves higher-dose Wegovy 7.2mg, Hims settles with Novo and becomes an authorized seller, Zepbound Medicare coverage starts at $50/mo, and Lilly's oral pill orforglipron faces its FDA decision date. Here's what it means for your provider choices.

Apr 1, 2026 By MatchGLP1 Research Team
Read
News

March 2026: Novo Nordisk Slashes Prices, Hims in Regulatory Crisis, and Medicare Coverage on the Horizon

The GLP-1 market is shifting dramatically - Novo Nordisk announces 50% price cuts for 2027, Hims faces lawsuits and SEC investigation, TrumpRx launches, and Medicare coverage nears. Here's what it means for your provider choices.

Mar 1, 2026 By MatchGLP1 Research Team
Read
News

February 2026: Major GLP-1 Provider Updates You Need to Know

A comprehensive roundup of significant changes across GLP-1 providers this month, including partnership shake-ups, pricing updates, and medication availability changes.

Feb 5, 2026 By MatchGLP1 Research Team
Read

Never Miss an Update

Pricing changes, new providers, and regulatory updates - we track it all so you can make informed decisions about your GLP-1 treatment.

Compare Providers View Rankings

Find the Right Provider

Compare GLP-1 providers and find the best option for your needs and budget.

Compare Providers